Audit: QRS - Functional Fitness for Health & Longevity
Audit conducted on 31/08/2026 05:32 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol, time-to-effect, gate, benefit, risk, monitoring and qualitative content traces to ER lines 243–287, 303–334, 356–376, 411, 441–461, 485–487. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | marker_7_target keeps the ER’s “No established target in trained people; track change from own rested baseline”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retained as absolutes; fluoroquinolone item keeps the full 4-week window. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gate items come only from ER Key Interactions & Contraindications; action_3 comes from the ER Therapeutic Protocol bullet, not from Benefit-Modifying Factors. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, author names or brands in the QRS; the named drug examples all appear in ER lines 305–321. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions anywhere in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Plain declarative register matching the ER, including its own “blood sugar”/”blood pressure” phrasing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and thresholds presented neutrally; at-a-glance frames both benefit and cost. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as documented practice, not instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions; gates are stated as conditions, not orders. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “should”, “recommended”, or “advised” in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the populated spans. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to the named conditions and biomarkers the gates and monitoring table require. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are single noun phrases; sub-lines are one clause each. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed across all spans; no “you”/”your”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal-range targets (25-hydroxyvitamin D 40–60 ng/mL, hs-CRP <1.0 mg/L, HbA1c 5.0–5.4%) address that audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Three weekly 45–60 min sessions and a ten-marker monitoring battery are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplified or motivational general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Injury is surfaced as the High-tier cost alongside the High-tier benefits, matching the ER’s weighting. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears only in the canonical topic; no “anti-aging” usage. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Myocardial infarction”, “rhabdomyolysis”, “25-hydroxyvitamin D” used as in the ER; no consumer-grade substitutions. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings byte-identical to the template (lines 446, 488, 533, 562, 590, 613, 641, 645–647, 797). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names present; marker_#* expanded to 1–10 and qualitative_item# to 1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The website="evidence_review", website="audit" and website="full_review" spans and all CSS/structure are unchanged from the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped into the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1/2/3 labels are verbatim ER bold labels (“Standard frequency and structure”, “Circuit format”, “Baseline biomarkers guiding entry”, ER lines 356, 358, 374). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-cell labels use the ER’s own terms from line 411 (“Falls reduction”, “Body composition”, strength/daily-task); marker names match the ER biomarker column. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the file; the ER’s ⚠️ Conflicted markers were stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the shortest wording that preserves the mandated qualifiers; no section carries ER explanatory prose. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- line 3, closing --- line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed entirely in an HTML comment; no duplicate on-page rendering. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: functional_fitness_2026-0831-0300_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0831-0520. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Functional Fitness for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches the ER canonical_topic with &. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/31/2026, from 2026-0831-0520. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header block is byte-identical to the template apart from the four variable spans. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses ER lines 485–487: pattern definition, strongest evidence, secondary gains, main cost. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct sentence in ER lines 485–487. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “squatting, hinging, lunging”, “everyday-task performance”, “blood-pressure and blood-sugar readings”; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial identifiers of any kind. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers at all. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to ER lines 309 and 325–334. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight “Populations who should avoid” entries plus the fluoroquinolone absolute contraindication (ER line 309). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine <li> elements, lines 565–585. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER glosses stripped (retinopathy bleeding clause, myocarditis and T-score definitions, angina/stenosis explanations); no dashes carry trailing content. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | NYHA Class IV, <90 days, 180/110 mmHg, 5,000 U/L, T-score below -3.5, six months, three months and the 4-week fluoroquinolone window all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER identifies such populations and the section is correctly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items trace to ER lines 305–323. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine of the ER’s ten interaction bullets; fluoroquinolones correctly excluded as a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements, lines 593–603. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All “— caution/monitor” clauses and mitigation sentences stripped; each item is a bare agent name plus examples. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug example lists retained for beta-blockers, statins, diuretics/SGLT2, anticoagulants and NSAIDs; the ER’s explanatory gloss inside the diuretic parenthesis is correctly dropped. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies ten such interactions and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to ER Therapeutic Protocol lines 356, 358, 374. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Frequency/structure, circuit format, and baseline biomarker entry criteria — the only three non-comparative, non-modifier bullets that define how the intervention is performed. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies at least three distinct actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated, lines 450–483, each matching the corresponding ER bullet. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Strength/daily tasks, falls reduction, and body composition — the three facts in ER line 411. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Two High-tier benefits first (everyday-task performance and falls), then the Low-tier body-composition benefit. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated, lines 494–526; values 6–12 weeks, 3–6 months, 3 months minimum match ER line 411. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All twelve entries match ER benefit headings, lines 145–219. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated, lines 535–555. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare benefit heading; no magnitude figures carried across. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any benefits entry; the ER’s “⚠️ Conflicted” markers stripped as well. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers contain items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven entries match ER risk headings, lines 243–287. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated, lines 615–635. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare risk heading; no prevalence or rate figures carried across. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risks entry. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers contain items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table rows and cadence taken from ER Monitoring Protocol & Defining Success, lines 439–452. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER table rows present, with targets matching (grip strength through bone mineral density T-score). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 788–791 reproduce the ER’s 12-week/six-month/annual schedule from line 439. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items taken from the ER’s qualitative marker list, lines 456–461. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present verbatim, lines 800–827. |
Issues 31/08/2026 05:32
Pass rate 100.00%. No issues found.
Issues 31/08/2026 05:25
- 2.7 — Unexpanded “TUG” acronym:
marker_4_nameat line 692 is the bare acronym “TUG”, a physiotherapy-specific term the ER itself expands as “TUG = Timed Up and Go” (ER line 446), leaving the QRS row unreadable without specialist knowledge. - 2.15 — Colloquial “reps” abbreviation:
marker_2_targetat line 669 reads “≥14 reps ages 60–64”, using gym-colloquial shorthand where the ER uses the formal term “repetitions” (ER line 444).
Fixes 31/08/2026 05:25
- 2.7 — TUG acronym expanded:
marker_4_namechanged from “TUG” to “Timed Up and Go”, the ER’s own expansion of the term. - 2.15 — Formal term for repetitions:
marker_2_targetchanged from “≥14 reps ages 60–64” to “≥14 repetitions ages 60–64”, matching the ER’s wording.